findmyKOL

Ula Jurkunas, MD

Basic profile

Massachusetts Eye and Ear Infirmary

ORCIDNPI
RegionBoston, MA · NortheastSpecialtyOphthalmologyFocusOphthalmology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH funding2010–2026Why? →

Ula Jurkunas is an Ophthalmology physician affiliated with Massachusetts Eye and Ear Infirmary. OpenAlex indexes 200 publications with 5,713 citations (h-index 43); ClinicalTrials.gov lists 4 registered studies matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
200publications

Distinct works indexed by OpenAlex, matched via ORCID.

5,713citations

Total citations across indexed works.

43h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
4clinical trials

Investigator role on registered studies.

View trials
4companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
4NIH grants · 2010–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

243 Charles St
Mass Eye And Ear Infirmary
Boston, MA 021143002

Telephone

617-573-6897

Registry record last updated 7 Jun 2013.

View the NPPES registry record

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    59.4%
    Corticosteroid49.7%
    Prednisolone Acetate66%Fluorometholone34%
    Part D93 patients
    Corticosteroids, plain7.4%
    Difluprednate39%Loteprednol Etabonate30%Lotemax30%
    Part D<11 patients

    + 1 more class in this area

  • Anti-infectives

    24.6%
    Macrolide11.7%
    Erythromycin100%
    Part D22 patients
    Fluoroquinolone Antibacterial9.2%
    Moxifloxacin100%
    Part D31 patients

    + 1 more class in this area

  • Dermatology

    5%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor5%
    Acyclovir100%
    Part D12 patients
Where care is delivered (Part B)92.5% facility · 7.5% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

4 NIH research awards on record, funded 20102026 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”